BioSpace News Archive

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 3,250 restricted stock units of Atara’s common stock to one newly hired employee.

Acorda Therapeutics, Inc. announced that it has completed the previously announced 1-for-20 reverse stock split of its outstanding and authorized shares of common stock.

Legend Biotech Corporation announced it will participate in the upcoming investor conferences.

Positive high-level results from a planned interim analysis of the MATTERHORN Phase III trial showed treatment with AstraZeneca’s IMFINZI® (durvalumab) added to standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) neoadjuvant.

ORIC Pharmaceuticals, Inc. announced that on June 1, 2023, ORIC granted a total of 3,380 non-qualified stock options and 560 restricted stock units to one new non-executive employee who began their employment with ORIC in May 2023.

Certara, Inc., a global leader in biosimulation, announced that Company management will participate in the Jefferies Global Healthcare Conference.

Olema Pharmaceuticals, Inc. announced that the Company granted stock options to two new employees to purchase an aggregate of 17,400 shares of the Company’s common stock, effective as of June 1, 2023.

Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the grant of an inducement award to the Company’s newly appointed Chief Financial Officer, Brian Piekos.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 12 presentations across its neuroscience portfolio featured at the Psych Congress Elevate 2023 Annual Meeting taking place on June 1-4, 2023.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to five new employees.